XML 14 R6.htm IDEA: XBRL DOCUMENT v3.23.2
Unaudited Condensed Consolidated Statements of Shareholders' Equity - USD ($)
$ in Thousands
Total
Ordinary GBP 0.00001 Par Value
Deferred Shares GBP 0.00001 Par Value
Deferred Shares GBP 100,000 Par Value
Additional Paid-in Capital
Accumulated other comprehensive gain (loss)
Accumulated Deficit
Accumulated Equity
Balance at Dec. 31, 2021       $ 137 $ 467,213 $ 9,472 $ (356,381) $ 120,441
Balance, Shares at Dec. 31, 2021   35,854,591 112,077 1        
Shares issued under employee share purchase plan         110     110
Shares issued under employee share purchase plan, Shares   149,254            
Vesting of restricted share units, Shares   30,863            
Forfeiture of ordinary shares, Shares   (4,826) 4,826          
Issuance of ordinary shares, net of issuance cost of $2,600         28,291     28,291
Issuance of ordinary shares, net of issuance cost of $2,600, Shares   28,848,968            
Cancellation of deferred shares, Shares     (93,451)          
Non-cash share-based compensation         2,835     2,835
Unrealized loss on foreign currency translation $ (10,968)         (10,968)   (10,968)
Net loss (51,080)           (51,080) (51,080)
Balance at Jun. 30, 2022       $ 137 498,449 (1,496) (407,461) 89,629
Balance, Shares at Jun. 30, 2022   64,878,850 23,452 1        
Balance at Dec. 31, 2021       $ 137 467,213 9,472 (356,381) 120,441
Balance, Shares at Dec. 31, 2021   35,854,591 112,077 1        
Balance at Dec. 31, 2022 52,414     $ 137 500,781 (3,151) (445,353) 52,414
Balance, Shares at Dec. 31, 2022   65,113,575 24,812 1        
Shares issued under employee share purchase plan         32     32
Shares issued under employee share purchase plan, Shares   217,755            
Vesting of restricted share units, Shares   50,677            
Forfeiture of ordinary shares, Shares   (12,590) 12,590          
Non-cash share-based compensation         2,048     2,048
Unrealized loss on foreign currency translation 2,212         2,212   2,212
Release of cumulative foreign currency translation adjustment, upon sale of Freeline Therapeutics GmbH           155   155
Net loss (14,845)           (14,845) (14,845)
Balance at Jun. 30, 2023 $ 42,016     $ 137 $ 502,861 $ (784) $ (460,198) $ 42,016
Balance, Shares at Jun. 30, 2023   65,369,417 37,402 1